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Abstract: In the scientific literature, the use of a surfactant is recommended for both designing quality control tests for 
water insoluble or sparingly water soluble drugs and for predicting the bioavailability of drugs from various types of for-
mulations. Since the number of poorly soluble drugs is increasing, the selection of adequate dissolution test for these be-
comes more and more important. The aim of the present study was to develop predictive and discriminatory test methods 
based on surfactants that are recommended in the literature. Particular respect was given to the use of sodium lauryl sul-
fate and Tween 80, the two most commonly used surfactants for this purpose. Tamoxifen was used as a model drug. Dis-
solution experiments were performed using various concentrations of the two surfactants in buffer media typically used to 
prepare biorelevant test media. Results were then compared with those deriving from the same test formulations in 
biorelevant and simplified “biorelevant” media. Results from this study indicate that the concentration of surfactant has a 
huge impact on both the rate and extent of drug release from the formulation and also on the discriminatory power of  
the test. However, they also indicate that a well designed and validated test medium containing SLS or Tween 80 can be 
useful in terms of establishing a discriminatory test medium that possibly could also be used to assure batch to batch  
bioequivalence. Therefore, the approach described in the present paper might be very helpful for developing predictive 
and discriminatory methods in early formulation development for poorly soluble drugs and which could also be adopted 
for QC.  
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INTRODUCTION 
  Simulation of gastrointestinal conditions is essential to 
adequately predict the in vivo behavior of poorly soluble 
drugs. Thus, simulating small intestinal conditions with 
biorelevant media such as fasted state simulated intestinal 
fluid (FaSSIF) and fed state simulated intestinal fluid 
(FeSSIF) has become standard practice in many dissolution 
laboratories [1-6]. However, due to their complex composi-
tion, these media are expensive and their stability is limited. 
Therefore, in a precursor study [7] selected media containing 
synthetic surfactants with physicochemical properties similar 
to those of FaSSIF and FeSSIF were identified. Such simpli-
fied “biorelevant” media can be used to replace biorelevant 
test media for screening formulations, if it can be shown that 
solubility and dissolution of the drug in these simplified me-
dia are similar to that in real biorelevant media prepared with 
bile components. But, the cited experiments have also shown 
that validation of the correspondence of results in media con-
taining synthetic surfactants with those containing bile com-
ponents is necessary on a case-by-case basis. They also indi-
cated that various types and concentrations of surfactants can 
result in very different dissolution profiles.  
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  In the scientific literature, the use of a surfactant is rec-
ommended for both designing quality control (QC) tests for 
water insoluble or sparingly water soluble drugs and for pre-
dicting the bioavailability of drugs from various types of 
formulations [8]. However, most of these references do not 
give any instructions on how to develop discriminative   
dissolution methods based on media containing surfactants 
and, they do not take into account the various physicochemi-
cal parameters that were taken into account when the simpli-
fied „biorelevant“ media were established [7]. Thus, particu-
larly for inexperienced analysts or at time points when in 
vivo data are not yet available the selection of adequate test 
conditions can represent a great challenge, where the choice 
of an inadequate model could result in both under- or 
overprediction of the in vivo dissolution behavior. Such a 
model might also lack of the discriminative power in terms 
of distinguishing between “good” and “bad” batches of a 
given formulation.  
  Thus, in the present series of tests results from real 
biorelevant media, i.e. FaSSIF and FeSSIF [1] and simplified 
“biorelevant” media having physicochemical properties that 
correspond to those of FaSSIF and FeSSIF [7] were com-
pared with those generated in media containing various con-
centrations of surfactants that are typically recommended in 
the literature [9-11]. Particular respect was given to two of 
the most commonly used surfactants, sodium lauryl sulfate 
(SLS) and Tween 80. Can Biorelevant Media be Simplified  The Open Drug Delivery Journal, 2010, Volume 4    31 
MATERIALS AND METHODS 
Materials 
  Tween 80 – Crillet
® 4 (polyoxyethylene sorbitan monoo-
leate), lot # 0000333555 (Croda Europe Ltd., East Yorkshire, 
England) and SLS (sodium lauryl (dodecyl) sulfate), 
lot  #  L56042192709 (VWR International Ltd., Poole, Eng-
land) were of analytical grade and purchased commercially. 
  Tamoxifen citrate (lot  #  SRP 01106t) was obtained   
from Sequoia Research Products Ltd., Pangbourne, UK.   
Tamoxifen Hexal 20  mg, lot  #  61MR19 (HEXAL AG, 
Holzkirchen, Germany) was purchased commercially. White 
opaque gelatin capsules (Wepa Nr. 35758 according to DAB 
10; size 1; 0.5 mL) were purchased from Wepa Apotheken-
bedarf GmbH & Co KG, Hillscheid, Germany. All other 
compounds were of analytical grade and purchased commer-
cially. 
Media Preparation 
  First, Blank FaSSIF pH 6.5 and Blank FeSSIF pH 5.0 
(i.e. the relevant buffers for the preparation of biorelevant 
media representing small intestinal conditions in the fasted 
or fed state) were prepared as follows: Blank FaSSIF was 
prepared by dissolving 3.438 g NaH2PO4 and 6.186 g of 
NaCl in 900 mL of demineralized water, adjusting the pH to 
6.5 by addition of 0.1 N NaOH solution and finally adjusting 
the volume to 1000.0 mL with demineralized water. Corre-
spondingly, Blank FeSSIF was prepared by dissolving 
11.874 g NaCl in 900 mL of demineralized water, adding 
8.65 g of glacial acetic acid, adjusting the pH to 5.0 with 0.1 
N NaOH solution and bringing the volume to 1000.0 mL by 
addition of demineralized water. Then simplified media con-
taining SLS and Tween 80 were prepared by adding the 
various concentrations, i.e. 0.1, 0.175, 0.25, 0.5, 0.75, 1.0 
and 1.5 % of the surfactants to each of the two buffers. Sub-
sequently, the media were placed in an ultrasonic bath for 15 
min and finally stirred for another 15 min on a magnetic stir-
rer before use. 
Selection of Model Drug Formulations and Test Parame-
ters 
  Since its oral bioavailability and dissolution rate per-
formance has been reported to depend on the presence of 
dissolution enhancers [12, 13], tamoxifen was selected as a 
model drug for the experiments. Tamoxifen is a BCS class II 
drug [14], meaning that its bioavailability is mainly deter-
mined by the rate and extent of tamoxifen dissolution. Re-
sults from preliminary experiments have also shown that 
drug release from various tamoxifen formulations is sensi-
tive to the composition of the test media. For these reasons, 
the drug appeared to be an optimal candidate to prove the 
applicability of simplified media on the basis of SLS and 
Tween 80. 
  The intention of the first series of tests was to find con-
centrations of SLS and Tween 80 which create tamoxifen 
dissolution profiles homomorphous to those obtained with 
FaSSIF, FeSSIF and simplified “biorelevant” media. These 
initial screening experiments were performed with a formu-
lation that in the precursor study did not exhibit complete 
drug release, but about 50 % dissolution in within the test 
duration. This formulation consisted of gelatin capsules, 
filled with  tablet Tamoxifen Hexal 20 mg and 15.17 mg of 
tamoxifen citrate. The resulting test dose was therefore 30.34 
mg tamoxifen citrate (= 20 mg tamoxifen) in all cases The 
formulations were subject to dissolution studies in Blank 
FaSSIF and Blank FeSSIF containing SLS or Tween 80 in 
the concentration range mentioned above. For comparison 
purposes, drug release of the intact Tamoxifen Hexal 20 mg 
tablet was also recorded in Blank FaSSIF and Blank FeSSIF. 
Results from these experiments were then compared with 
those obtained with the corresponding formulation in simpli-
fied “biorelevant” FaSSIF and FeSSIF in the precursor study 
[7]. Finally, the surfactant concentrations that resulted in 
dissolution profiles similar to those in the precursor study 
were selected for further experiments. 
  The focus of the second part of the study was to elucidate 
the discriminatory power of the selected SLS and Tween 80 
media. For this purpose, a set of “good” and “bad” batches 
of a tamoxifen citrate formulation was generated. Similar to 
the precursor study, neither different batches of a formula-
tion nor in vivo data were available at the time of the ex-
periment. The latter situation displays a typical moment in 
early formulation development when prototypes for pilot 
bioavailability studies need to be selected. For the above 
mentioned reasons and to better compare current results with 
those obtained with simplified “biorelevant” media [7], the 
compromise was to perform the release experiments with 
different qualities of a “self-made” capsule formulation con-
taining mixtures of different ratios of the poorly soluble pure 
drug and partial tablets of the same drug. 
Dissolution Studies 
  Drug release experiments were performed with USP Ap-
paratus 2 (Paddle, DT 600 and DT 700, Erweka, Germany). 
Each vessel was filled with 500 mL of medium, and an agita-
tion speed of 75  rpm was used for all dissolution studies 
[15]. Experiments were run in triplicate. Samples (5  mL) 
were removed after 5, 10, 15, 20, 30, 45, 60, 90, and 120 min 
using a glass syringe and, immediately filtered through   
a 0.45 m Teflon
® filter (FP 030/2, Whatman, Schleicher & 
Schuell GmbH, Dassel, Germany). To keep the test volume 
constant throughout the entire test, the sample volume was 
replace by fresh preheated (37°C) medium. 
UV Analysis 
  All samples were analyzed at 275 nm using a UV-
spectrophotometer (U  2000/3000, Hitachi Ltd, Tokyo, Ja-
pan) equipped with a 5  mm cuvette. A separate standard 
calibration curve was prepared in each of the media tested. 
RESULTS AND DISCUSSION  
 Figs.  (1 and 2) display a copy of the results obtained in 
the precursor study where, as mentioned before, the “self-
made” tamoxifen formulations represented very good candi-
dates for examining the discriminatory power of simplified 
“biorelevant” test media. In Blank FaSSIF and Blank FeS-
SIF, the Tamoxifen Hexal 20 mg tablets showed a poor dis-
solution performance, i.e. in Blank FaSSIF only 10  % of 
drug stayed in solution within the test duration of 120 min 
and in Blank FeSSIF about 35 % of the drug was released. 
However, in biorelevant and simplified “biorelevant” test 
media, the tablet formulation showed almost complete drug 32    The Open Drug Delivery Journal, 2010, Volume 4  Taupitz and Klein 
release. The pure drug in contrast showed a relatively poor 
dissolution behavior in both biorelevant and simplified 
“biorelevant” test media (< 35 % drug release within 120 
min). Due to the significantly different dissolution perform-
ances of the tablet formulation and the pure drug, dissolution 
profiles of the different “self-made” test formulations could 
be clearly rank-ordered in terms of the ratio of their 
ingredients. 
  The objective of the present series of tests was first to 
find SLS- and Tween 80 based media that result in dissolu-
tion profiles that are superimposable to those obtained with 
the simplified “biorelevant” media. Thus, in the first set of 
experiments gelatin capsules filled with  tablet Tamoxifen 
Hexal 20 mg and 15.17 mg of tamoxifen citrate were exam-
ined in Blank FaSSIF and Blank FeSSIF containing SLS or 
Tween 80 in the concentration range of 0.1-1.5 %. 
  Results of these experiments (data not shown here) indi-
cated that dissolution profiles in media containing 0.1-0.5 % 
SLS and 0.1-0.25 % Tween 80 come very close to the target 
profiles. Concentrations of 0.1 % SLS and 0.175 % Tween 
80 were selected as the lowest applicable concentrations that 
can be used to resemble dissolution profiles obtained in 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Drug release of Tamoxifen Hexal 20 mg, Tamoxifen Hexal/tamoxifen citrate mixtures, and tamoxifen citrate in media simulating 
the fasted state:  Blank FaSSIF,  FaSSIF,  & : simplified “biorelevant” FaSSIF (copied with permission from Dissolution Technolo-
gies 2007, 14 (4): p. 8-13). 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Drug release of Tamoxifen Hexal 20 mg, Tamoxifen Hexal/tamoxifen citrate mixtures, and tamoxifen citrate in media simulating 
the fed state:  Blank FeSSIF,  FeSSIF,  & : simplified “biorelevant” FeSSIF (copied with permission from Dissolution Technologies 
2007, 14 (4): p. 8-13). Can Biorelevant Media be Simplified  The Open Drug Delivery Journal, 2010, Volume 4    33 
FaSSIF/FeSSIF and the simplified “biorelevant” media   
established in the precursor study (see results for  tablet 
Tamoxifen Hexal 20 mg and 15.17 mg of tamoxifen citrate 
in Figs. 1 and 2). 
  As another intention of the study was to design test me-
dia having a discriminatory power comparable to that of the 
“simplified” biorelevant media, in the next set of experi-
ments, the selected media were systemically screened for 
their discriminatory power, i.e. they were used to screen the 
dissolution behavior of different qualities of a “self-made” 
capsule formulation. The results of these experiments are 
shown in Figs. (3-6). 
  Even if the same concentration of SLS or Tween 80 was 
used to simulate both, the fasted and the fed state, results 
obtained with the new set of media came close to that ob-
tained with the physiologically based media. This was par-
ticularly the case for the simplified FaSSIF media. Figs. (3 to 
6) clearly indicate that the new media have an adequate dis-
criminatory power. Like with the simplified “biorelevant” 
media, in all cases it was possible to distinguish between the 
different compositions of the formulations tested. However, 
it needs to be mentioned that even if the profiles in the dif-
ferent media came close to each other, some profiles showed 
marked differences in the rate and extent of initial drug re-
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Drug release of Tamoxifen Hexal 20 mg, Tamoxifen Hexal/tamoxifen citrate mixtures, and tamoxifen citrate in media simulating 
the fasted state:  Blank FaSSIF,  FaSSIF,  & : Blank FaSSIF with 0.1 % SLS. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Drug release of Tamoxifen Hexal 20 mg, Tamoxifen Hexal/tamoxifen citrate mixtures, and tamoxifen citrate in media simulating 
the fed state:  Blank FeSSIF,  FeSSIF,  & : Blank FeSSIF with 0.1 % SLS. 34    The Open Drug Delivery Journal, 2010, Volume 4  Taupitz and Klein 
lease from the formulations. Overall, as already observed in 
the precursor study, with the simplified media it was much 
more difficult to simulate drug release in FeSSIF. It could be 
noted that in simulated FeSSIF containing 0.175 % Tween 
80 (see Fig. 6) the initial drug release rate was smaller than 
in simplified “biorelevant” FeSSIF and original FeSSIF. 
Nevertheless, the amount of drug released after a total test 
time of 120 min was again similar to that in corresponding 
reference media. As can be seen in Figs. (7-10), similarity to 
the results in simplified “biorelevant” media was definitely 
no longer guaranteed when the same set of experiments was 
performed with media containing higher concentrations of 
the two surfactants.  
 Figs.  (7-10) show the dissolution profiles of the test   
formulations in media containing 1  % SLS or Tween 80. 
Comparison of these dissolution profiles with those shown in 
Figs. (3-6) clearly indicates that not only the type of surfac-
tant but also the choice of the surfactant concentration has a 
huge impact on both the rate and extent of in vitro drug re-
lease and also the discriminatory power of the test method. 
As discussed before, the use of the media containing 0.1 % 
SLS and 0.175  % Tween 80 resulted in an excellent dis-
criminatory power of the test system. Although the use of 
higher concentrations of the two surfactants, i.e. 1 % SLS 
and 1 % Tween 80, enabled to achieve a better simulation of 
the initial release rate in some of the experiments, these con-
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Drug release of Tamoxifen Hexal 20 mg, Tamoxifen Hexal/tamoxifen citrate mixtures, and tamoxifen citrate in media simulating 
the fasted state:  Blank FaSSIF,  FaSSIF,  & : Blank FaSSIF with 0.175 % Tween 80. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Drug release of Tamoxifen Hexal 20 mg, Tamoxifen Hexal/tamoxifen citrate mixtures, and tamoxifen citrate in media simulating 
the fed state:  Blank FeSSIF,  FeSSIF,  & : Blank FeSSIF with 0.175 % Tween 80.  Can Biorelevant Media be Simplified  The Open Drug Delivery Journal, 2010, Volume 4    35 
centrations turned out to be unfeasible in terms of discrimi-
nating between the different test formulations. After the total 
test time of 120 min in the media containing 1 % of surfac-
tant nearly the same amount of drug was released from all 
test formulations and even the pure drug did completely dis-
solved in this time frame. This implies a very poor discrimi-
natory power of this test setup. This observation was also 
supported by the standard deviations calculated for the aver-
age drug release from triplicate measurements. For all pro-
files in media containing 1 % of surfactant the standard de-
viations were significantly higher than those obtained in me-
dia containing 0.1 % SLS and 0.175 % Tween 80, respec-
tively. 
  It can be summarized that based on the results obtained 
in the present study, commonly used surfactants like SLS 
and Tween 80 represent excipients that can be very useful in 
the development of discriminatory dissolution tests for for-
mulations containing poorly soluble compounds. However, 
results from the present study also indicate the importance of 
screening for the right medium composition. Even if meth-
ods applying up to 5 % SLS and up to 2 % Tween 80 are 
described in international pharmacopoeia and guidances [9, 
11], such methods should not be simply adapted to other 
drug products. The results presented here suggest that an 
uncritical use of methods described in the literature is likely 
to come along with test methods that will be anything but 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Drug release of Tamoxifen Hexal 20 mg, Tamoxifen Hexal/tamoxifen citrate mixtures, and tamoxifen citrate in media simulating 
the fasted state:  Blank FaSSIF,  FaSSIF,  & : Blank FaSSIF with 1 % SLS. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (8). Drug release of Tamoxifen Hexal 20 mg, Tamoxifen Hexal/tamoxifen citrate mixtures, and tamoxifen citrate in media simulating 
the fed state:  Blank FeSSIF,  FeSSIF,  & :: Blank FeSSIF with 1 % SLS.  36    The Open Drug Delivery Journal, 2010, Volume 4  Taupitz and Klein 
predictive for in vivo drug release and with respect to QC 
purposes will most likely also lack of discriminatory power 
in terms of assuring batch to batch bioequivalence for new 
drug products. 
CONCLUSION 
  The approach described in the present paper can help to 
develop drug release tests which, even if based on the use of 
non-physiological surfactants and without taking into ac-
count all relevant physicochemical parameters at the sites of 
drug release and absorption, might feature a certain grade of 
predictive power for the in vivo drug performance of new 
drug formulations. Although the validation of such test   
systems will require some time, all in all this procedure will  
be of great benefit for the user since for routine analysis   
well designed simplified media come along with various 
advantages which include the discriminatory power, the 
in vivo predictivity and, particularly when compared with   
the use of physiological surfactants, the time- and cost   
efficiency. Thus, provided it can be shown that solubility and 
dissolution of the drug and some selected preformulations   
in these simplified media are similar to that in biorelevant 
media prepared with bile components, simplified media   
can be very useful in the course of both screening various 
prototypes and developing quality control tests of a given 
drug formulation. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (9). Drug release of Tamoxifen Hexal 20 mg, Tamoxifen Hexal/tamoxifen citrate mixtures, and tamoxifen citrate in media simulating 
the fasted state:  FaSSIF, : Blank FaSSIF with 1 % Tween 80. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (10). Drug release of Tamoxifen Hexal 20 mg, Tamoxifen Hexal/tamoxifen citrate mixtures, and tamoxifen citrate in media simulating 
the fed state:  FeSSIF, : Blank FeSSIF with 1 % Tween 80.  Can Biorelevant Media be Simplified  The Open Drug Delivery Journal, 2010, Volume 4    37 
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